Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted under the skin, which can cause discomfort. Additionally, a viscoelastic ...

CGM devices use a small filament inserted under the skin, usually on the back of the upper arm or abdomen, to continuously measure glucose levels in interstitial fluid. The CGM wirelessly ...